The objective of the Gynecologic Oncology Group (GOG) is to improve the treatment results in patients with gynecologic cancer through the cooperative efforts of the multiple disciplines of gynecologic oncology, radiation oncology, medical oncology, pathology, immunology, and other disciplines where appropriate. This involves planning, initiation, execution, analysis, and recording of research methods related to management of patients with gynecologic malignancies. Bowman Gray School of Medicine of Wake Forest University has entered more patients onto protocol studies than any other membe institution in the GOG. Close coordination of the activities at this institution between the multiple disciplines has progressively improved since Bowman Gray joined the group in 1976. Our goal during 1985-89 is to continue our leadership role in participation in group studies by entry of the maximum number of patients in GOG protocols. We plan to participate in all protocols during the coming years. Finally, extensive involvement in multiple GOG committees by representation of all disciplines will be continued as well as continuing to have multiple Bowman Gray investigators serve as Protocol Study Chairmen.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA021946-10S2
Application #
3556639
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-06-01
Project End
1989-06-30
Budget Start
1987-05-01
Budget End
1989-06-30
Support Year
10
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
Schools of Medicine
DUNS #
041418799
City
Winston-Salem
State
NC
Country
United States
Zip Code
27106
Barr, Paul M; Li, Hongli; Spier, Catherine et al. (2015) Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol 33:2399-404
Sutton, Gregory; Axelrod, Janice H; Bundy, Brian N et al. (2006) Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 100:349-54
Tate Thigpen, J; Blessing, John A; DeGeest, Koen et al. (2004) Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol 93:336-9
Thigpen, J Tate; Blessing, John A; Olt, George et al. (2003) Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 90:581-6
Keys, Henry M; Bundy, Brian N; Stehman, Frederick B et al. (2003) Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol 89:343-53
Spirtos, Nick M; Westby, Cynthia M; Averette, Hervy E et al. (2002) Blood transfusion and the risk of recurrence in squamous cell carcinoma of the cervix: a gynecologic oncology group study. Am J Clin Oncol 25:398-403
Zaino, R; Whitney, C; Brady, M F et al. (2001) Simultaneously detected endometrial and ovarian carcinomas--a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol Oncol 83:355-62
McGuire, W P; Hoskins, W J; Brady, M F et al. (1995) Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 13:1589-99
Barrett, R J; Blessing, J A; Homesley, H D et al. (1993) Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 16:494-6
Omura, G A; Brady, M F; Homesley, H D et al. (1991) Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 9:1138-50

Showing the most recent 10 out of 15 publications